G. Logan

Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.

H. Linden, G. Hortobagyi, L. Pusztai, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma

M. Salto‐Tellez, R. Fitzgerald, R. Turkington, 2019, Gut.

Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology.

I. Mills, D. Neal, H. Pandha, 2017, European urology.

DEK oncogene expression during normal hematopoiesis and in Acute Myeloid Leukemia (AML).

D. Markovitz, K. Mills, M. Percy, 2015, Blood cells, molecules & diseases.

In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer

M. Salto‐Tellez, U. McDermott, P. Johnston, 2020, Clinical Cancer Research.

Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer

G. Irwin, R. Kennedy, K. Savage, 2021, British journal of cancer.

Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer

G. Irwin, R. Kennedy, K. Savage, 2021, British Journal of Cancer.

Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy

I. Mills, D. McArt, S. McDade, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

oncogene expression during normal hematopoiesis and in Acute Myeloid Leukemia ( AML ) ☆

D. Markovitz, K. Mills, M. Percy, 2017 .

DEK oncogene expression during normal hematopoiesis and in Acute Myeloid Leukemia (AML).

D. Markovitz, K. Mills, M. Percy, 2015, Blood cells, molecules & diseases.